Importantly, the value of the MEN1611 therapy may be general for the treatment of brain tumors and not be limited to Shh-type MBs alone, because selective inhibition of the PI3K/AKT/mTOR pathway appears to be a promising strategy also in Wnt-type MBs (101), in Group 3 MBs (102, 103) and in gliomas (104). Here, AKT1 is linked to Mobius syndrome.